Gerard H. A. Visser,corresponding author 1 , 2 Trude Thommesen, 2 , 3 Gian Carlo Di Renzo, 2 Anwar H. Nassar, 1 Steven L. Spitalnik, 2 and FIGO Committee for Safe Motherhood, Newborn Health
Int J Gynaecol Obstet. 2021 Feb; 152(2): 144–147.
Published online 2021 Jan 9. doi: 10.1002/ijgo.13459
PMCID: PMC7898700
PMID: 33128246
FIGO/ICM guidelines for preventing Rhesus disease: A call to action
Gerard H. A. Visser,corresponding author 1 , 2 Trude Thommesen, 2 , 3 Gian Carlo Di Renzo, 2 Anwar H. Nassar, 1 Steven L. Spitalnik, 2 and FIGO Committee for Safe Motherhood, Newborn Health
Author information Article notes Copyright and License information Disclaimer
Go to:
Abstract
The introduction of anti‐Rh(D) immunoglobulin more than 50 years ago has resulted in only a 50% decrease in Rhesus disease globally owing to a low uptake of this prophylactic approach. The International Federation of Gynecology and Obstetrics, International Confederation of Midwives, and Worldwide Initiative for Rhesus Disease Eradication have reviewed current evidence regarding the utility of anti‐Rh(D) immunoglobulin. Taking into account the effectiveness anti‐Rh(D), the new guidelines propose adjusting the dose for different indications and prioritizing its administration by indication.
Keywords: Anti‐D immunoglobulin, FIGO, Guidelines, International Confederation of Midwives, Prophylaxis, Rhesus disease, Worldwide Initiative for Rhesus Disease Eradication